These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16696194)

  • 21. Quality control analytical methods: strategies to ensure a robust quality-control microbiology program.
    Griffiths T; Connors A
    Int J Pharm Compd; 2013; 17(2):130-4. PubMed ID: 23696174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid/automated ID methods survey. PDA Microbial ID Task Force. Parenteral Drug Association.
    J Parenter Sci Technol; 1990; 44(4):216-22. PubMed ID: 2213430
    [No Abstract]   [Full Text] [Related]  

  • 23. Laboratory considerations of United States Pharmacopeia Chapter <71> sterility tests and its application to pharmaceutical compounding.
    Hyde TD
    Int J Pharm Compd; 2014; 18(1):46-52. PubMed ID: 24881341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 25. Natural product drug discovery: the times have never been better.
    Galm U; Shen B
    Chem Biol; 2007 Oct; 14(10):1098-104. PubMed ID: 17961822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. United States Parmacopeia Chapter <797> timeline: 1989 to 2013.
    Newton DW
    Int J Pharm Compd; 2013; 17(4):283-8. PubMed ID: 24261142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microbial diversity in pharmaceutical product recalls and environments.
    Jimenez L
    PDA J Pharm Sci Technol; 2007; 61(5):383-99. PubMed ID: 18047177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An industry commentary on regulatory issues--microbiology.
    Moldenhauer JE
    PDA J Pharm Sci Technol; 2002; 56(2):60-4. PubMed ID: 11977405
    [No Abstract]   [Full Text] [Related]  

  • 29. Continuous Microbiological Environmental Monitoring for Process Understanding and Reduced Interventions in Aseptic Manufacturing.
    Weber J; Hauschild J; Ijzerman-Boon P; Forng RY; Horsch J; Yan L; Prasad A; Henry RB; Claassen M; Villari P; Shereefa S; Wyatt J; Bolden JS; Pycke JT; Dassu D
    PDA J Pharm Sci Technol; 2019; 73(2):121-134. PubMed ID: 30361285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbial Identification in Pharmaceutical Compounding.
    Hyde T; Anstead J; Schade L; Zellner J
    Int J Pharm Compd; 2016; 20(1):13-8. PubMed ID: 27125052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation study on how to avoid microbial contamination during pharmaceutical production.
    Shintani H
    Biocontrol Sci; 2015; 20(1):1-10. PubMed ID: 25817807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Why and how to implement a rapid sterility test.
    Gressett G; Vanhaecke E; Moldenhauer J
    PDA J Pharm Sci Technol; 2008; 62(6):429-44. PubMed ID: 19634346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Environmental and Personnel Monitoring Programs-A Risk-Based Case Study of
    Tidswel EC; Boone K
    PDA J Pharm Sci Technol; 2020; 74(4):408-422. PubMed ID: 32060223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative Microbial Risk Assessment of Pharmaceutical Products.
    Eissa ME
    PDA J Pharm Sci Technol; 2017; 71(3):245-251. PubMed ID: 27974628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1.
    Martin M
    Int J Pharm Compd; 2018; 22(5):401-404. PubMed ID: 30384338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Environmental Monitoring in a Pharmaceutical Manufacturing Facility Using a Culture Independent Approach].
    Kawai M
    Yakugaku Zasshi; 2022; 142(1):33-37. PubMed ID: 34980749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 38. Environmental microbial challenges to an aseptic Blow-Fill-Seal process--a practical study.
    Jones DJ; Topping P; Sharp J
    PDA J Pharm Sci Technol; 1995; 49(5):226-34. PubMed ID: 7489196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of Milliflex
    Gordon O; Goverde M; Staerk A; Roesti D
    PDA J Pharm Sci Technol; 2017; 71(3):206-224. PubMed ID: 28196917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.